Selected publications

An epigenome-wide analysis of sex hormone levels and DNA methylation in male blood samples. 
Epigenetics. 2023;18(1):2196759.
Harbs J, Rinaldi S, Keski-Rahkonen P, Liu X, Palmqvist R, Van Guelpen B, Harlid S. 

Altered plasma metabolite levels can be detected years before a glioma diagnosis 
JCI Insight. 2023;8(19):e171225.
Löding S, Andersson U, Kaaks R, Schulze MB, Pala V, Urbarova I,  Amiano P, Colorado-Yohar SM, Guevara M, Heath AK, Chrysovalantou CA, Johansson M, Nyberg L, Antti H, Björkblom B, Melin B.

Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases. 
Int J Cancer. 2022;151(3):348-360.
Harlid S, Van Guelpen B, Qu C, Gylling B, Aglago EK, Amitay EL, Brenner H, Buchanan DD, Campbell PT, Cao Y, Chan AT, Chang-Claude J, Drew DA, Figueiredo JC, French AJ, Gallinger S, Giannakis M, Giles GG, Gunter MJ, Hoffmeister M, Hsu L, Jenkins MA, Lin Y, Moreno V, Murphy N, Newcomb PA, Newton CC, Nowak JA, Obón-Santacana M, Ogino S, Potter JD, Song M, Steinfelder RS, Sun W, Thibodeau SN, Toland AE, Ugai T, Um CY, Woods MO, Phipps AI, Harrison T, Peters U.

Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study. 
J Natl Cancer Inst. 2022;114(1):38-46.
Lu SSM, Mohammed Z, Häggström C, Myte R, Lindquist E, Gylfe Å, Van Guelpen B, Harlid S. 

Pre-diagnostic levels of sVEGFR2, sTNFR2, sIL-2Rα and sIL-6R are associated with glioma risk: A nested case-control study of repeated samples.
Cancer Med. 2022;11(4):1016-1025.
Wu WY, Späth F, Wibom C, Björkblom B, Dahlin AM, Melin B.

Prediagnostic biomarkers for early detection of glioma: using case-control studies from cohorts as study approach
Neuro-Oncology Advances. 2022;4: II73-II80.
Wu WY, Dahlin AM, Wibom C, Björkblom B, Melin B.

Circulating Sex Hormone Levels and Colon Cancer Risk in Men: A Nested Case-Control Study and Meta-analysis.
Cancer Epidemiol Biomarkers Prev. 2022;31(4):793-803.
Harbs J, Rinaldi S, Gicquiau A, Keski-Rahkonen P, Mori N, Liu X, Kaaks R, Katzke V, Schulze MB, Agnoli C, Tumino R, Bueno-de-Mesquita B, Crous-Bou M, Sanchez MJ, Aizpurua A, Chirlaque-López MD, Barricarte Gurrea A, Travis RC, Watts EL, Christakoudi S, Tsilidis KK, Weiderpass E, Gunter MJ, Van Guelpen B, Murphy N, Harlid S. 

Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients.
Exp Hematol Oncol. 2022;11(1):8.
Tahiru W, Izarra Santamaria A, Hultdin J, Wu WY, Späth F.

A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk.
Sci Rep. 2021;11(1):5151.
Harlid S, Harbs J, Myte R, Brunius C, Gunter MJ, Palmqvist R, Liu X, Van Guelpen B.

Intraindividual Long-term Immune Marker Stability in Plasma Samples Collected in Median 9.4 Years Apart in 304 Adult Cancer-free Individuals.
Cancer Epidemiol Biomarkers Prev. 2021;30(11):2052-2058.
Späth F, Wu WY, Krop EJM, Bergdahl IA, Wibom C, Vermeulen R.

Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples.
Haematologica. 2019;104(12):2456-2464.
Späth F, Wibom C, Krop EJM, Santamaria AI, Johansson AS, Bergdahl IA, Hultdin J, Vermeulen R, Melin B.

Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study.
Tumour Biol. 2016 Aug;37(8):11065-72.
Späth F, Andersson U, Dahlin AM, Langseth H, Hovig E, Johannesen TB, Grankvist K, Björkblom B, Wibom C, Melin B